UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

Clinical & translational oncology, 2021-08, Vol.23 (8), p.1520-1528

2021

Link zum Volltext

Verfügbarkeit prüfen

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

Annals of oncology, 2020-07, Vol.31, p.S242-S243

2020

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii184

2018

Link zum Volltext

Verfügbarkeit prüfen

Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii164

2018

Link zum Volltext

Verfügbarkeit prüfen

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Annals of oncology, 2018-10, Vol.29, p.viii45-viii45

2018

Link zum Volltext

Verfügbarkeit prüfen

AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

Annals of oncology, 2018-10, Vol.29, p.viii203-viii203

2018

Link zum Volltext

Verfügbarkeit prüfen

P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience

Annals of oncology, 2021-07, Vol.32, p.S137

2021

Link zum Volltext

Verfügbarkeit prüfen

P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

Annals of oncology, 2020-07, Vol.31, p.S115

2020

Link zum Volltext

Verfügbarkeit prüfen

O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites

Annals of oncology, 2020-07, Vol.31, p.239-240

2020

Link zum Volltext

Verfügbarkeit prüfen

Un caso de cáncer ovárico de célula pequeña hipercalcémico

Oncología (Barcelona), 2007, Vol.30 (2), p.48-52

2007

Link zum Volltext

Verfügbarkeit prüfen

Proyecto adapta: adecuación del tratamiento en dolor irruptivo oncológico

Revista de la Sociedad Española del Dolor, 2019, Vol.26 (1), p.31-42

2019

Link zum Volltext

Verfügbarkeit prüfen

2027P - VHIO-300 and a thousand and one nights: A tale of precision medicine

Annals of oncology, 2019-10, Vol.30, p.v810-v811

2019

Link zum Volltext

Verfügbarkeit prüfen

VHIO-300 and a thousand and one nights: A tale of precision medicine

Annals of oncology, 2019-10, Vol.30, p.v810-v811

2019

Link zum Volltext

Verfügbarkeit prüfen

Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

Annals of oncology, 2019-10, Vol.30, p.v42

2019

Link zum Volltext

Verfügbarkeit prüfen

135P - Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

Annals of oncology, 2019-10, Vol.30, p.v42-v42

2019

Link zum Volltext

Verfügbarkeit prüfen

550PEvaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

487PPatient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

611TiPAVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(65)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Life Sciences & Biomedicine
(6)
Humans
(5)
Mutation
(4)
Oncology
(4)
Medicine, General & Internal
(3)
Adult
(2)
Aged
(2)
Aged, 80 And Over
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Archaeology
(2)
Cancer
(2)
Chemotherapy
(2)
Colorectal Cancer
(2)
Colorectal Carcinoma
(2)
Colorectal Neoplasms - Drug Therapy
(2)
Colorectal Neoplasms - Genetics
(2)
Energy
(2)
Female
(2)
Fluorouracil - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer

Evaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay

Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study

Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

AVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience

P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites

Un caso de cáncer ovárico de célula pequeña hipercalcémico

Proyecto adapta: adecuación del tratamiento en dolor irruptivo oncológico

585P - POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

POLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

2027P - VHIO-300 and a thousand and one nights: A tale of precision medicine

VHIO-300 and a thousand and one nights: A tale of precision medicine

625P - Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

135P - Can we improve patient selection for phase I clinical trials (phI1) based on immuno-oncology score prognostic index (VIO)?

550PEvaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay

487PPatient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study

143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)

110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

611TiPAVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02)

Suchergebnisse filtern